Quantum BioPharma (NASDAQ: QNTM) has entered into a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302, known as Lucid-MS, for multiple sclerosis (MS), according to a NEWMEDIAWIRE release. The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial, with Thermo Fisher supporting study start-up and related clinical research services through its PPD Clinical Research Business.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. This mechanism represents a novel approach to treating MS, which currently has limited options for progressive forms.
For investors and the biopharmaceutical industry, this agreement signals tangible progress for Quantum BioPharma (NASDAQ: QNTM) in advancing its lead compound. The involvement of Thermo Fisher, a global leader in clinical research, lends credibility and operational expertise to the trial. Success in Phase 2 could position Lucid-MS as a breakthrough therapy for progressive MS, a condition with significant unmet medical need. The trial's start-up phase is a critical step before patient enrollment begins, and timely execution could accelerate the path to potential commercialization.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Beyond MS, Quantum invented UNBUZZD, an alcohol misuse treatment, and retains a 19.84% ownership in Unbuzzd Wellness Inc., with royalty agreements that could yield up to $250 million. However, the MS program remains central to its pipeline.
The Phase 2 trial's design, targeting progressive MS, addresses a high-risk, high-reward area. If successful, Lucid-MS could fill a gap where few effective treatments exist. The agreement with Thermo Fisher also underscores the company's ability to secure top-tier partners, which may boost investor confidence. As the trial progresses, data readouts will be closely watched by stakeholders.
To view the full press release, visit https://ibn.fm/CZH9U. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
